PDCD1 and neoplasm: Thus, blocking the PD‐1 pathway has become a key direction to abolish immune suppression for immunotherapy, and the development of monoclonal antibodies targeting PD‐1 or PD‐L1 has been a research ‘hot spot’ of tumor immunotherapy in recent years [10, 11, 12, 13, 14, 15].